Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GALR3 | O60755 | 1/20 | 0.33 |
| ▸ | PDE2A | O00408 | 2/20 | 0.33 |
| ▸ | PROKR1 | Q8TCW9 | 4/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | SPR | P35270 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18304968 | 0.82 | CHEK1 (0.31) | — | |
| SCHEMBL20138233 | 0.77 | GALR3 (0.36) | GALR3PROKR1SMN1; SMN2ALDH1A1SPR | |
| SCHEMBL18305061 | 0.76 | FPR2 (0.33) | PROKR1SMN1; SMN2ALDH1A1 | |
| SCHEMBL20138094 | 0.74 | FYN (0.36) | — | |
| SCHEMBL20138209 | 0.70 | CYP11B2 (0.36) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL20138158 | 0.70 | GALR3 (0.37) | GALR3PDE2APROKR1SMN1; SMN2ALDH1A1 | |
| SCHEMBL18304989 | 0.70 | PIK3CA (0.35) | PDE2A | |
| SCHEMBL20138039 | 0.69 | GALR3 (0.36) | GALR3PROKR1SMN1; SMN2ALDH1A1SPR | |
| SCHEMBL20138119 | 0.68 | GRIN1 (0.37) | PROKR1 | |
| SCHEMBL18305043 | 0.68 | GALR3 (0.35) | GALR3PROKR1SPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107873031-B | Benzoxazinone derivatives and analogs thereof as modulators of TNF activity | UCB生物制药私人有限公司 | 2021-03-12 | — | — | CN | disclosed |
| US-10287299-B2 | Substituted benzo[b][1,4]oxazines and pyrido[3,2-b][1,4]oxazines as modulators of tumor necrosis factor activity | UCB BIOPHARMA SPRL (BE) | 2019-05-14 | — | — | US | disclosed |
| US-20180134728-A1 | Benzoxazinone Derivatives and Analogues Thereof as Modulators of TNF Activity | UCB S.A. (BE) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180134728-A1 | Benzoxazinone Derivatives and Analogues Thereof as Modulators of TNF Activity | TNF, NFKBIA, TNFRSF1A | GALR3 1922/4885PDE2A 766/4885PROKR1 3147/4885 |
| US-10287299-B2 | Substituted benzo[b][1,4]oxazines and pyrido[3,2-b][1,4]oxazines as modulators of tumor necrosis factor activity | TNF, TNFRSF1A, NFKBIA | GALR3 1578/4885PDE2A 571/4885PROKR1 2443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.